Pioneering a New World of Medicine
with Bubbles and Ultrasound
In solid tumors such as pancreatic cancer and in central nervous system disorders, biological barriers remain a major obstacle to effective drug delivery.
Wellthera has developed BUS-DDS (Bubble Ultrasound-mediated Drug Delivery System), an innovative platform that combines therapeutic microbubbles with low-intensity ultrasound.
BUS-DDS enables drugs to cross previously inaccessible biological barriers, expanding the therapeutic potential of both existing and novel medicines and creating new treatment opportunities.
Stay up to date with our latest announcements, research activities, and events.
Notice of Website Update
We are pleased to announce that our corporate website has been updated. This update includes a reorganization of information related to our business activities, along
Notice of Capital Reduction
Wellthera Co., Ltd. announces that, effective 30 November 2025, the company has completed a reduction of its share capital as outlined below. Details of
Change in the Board of Directors
On October 17, 2025, Mr. Hodaka Nakanishi resigned from his position as a Director of the Company. Accordingly, at the extraordinary general meeting of shareholders
Wellthera is a spin-off from Teikyo University, developing proprietary technologies based on therapeutic microbubbles and ultrasound.
With a strong focus on clinical translation, we are building a platform that advances drug delivery and supports the development of next-generation therapies.
We welcome inquiries about collaborative research, business partnerships, and investor relations.